2013 Fiscal Year Final Research Report
Development of immunotherapy against regulatory T cells targeting a new biomarker, VEGFR2
| Project/Area Number |
23591894
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
ONISHI Hideya 九州大学, 医学(系)研究科(研究院), 准教授 (30553276)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KATANO Mitsuo 九州大学, 大学院医学研究院, 教授 (10145203)
NAKANO Kenji 九州大学, 先端融合医療レドックスナビ 研究拠点, 教授 (00315061)
NAKAMURA Katsuya 九州大学, 大学病院, 助教 (60585743)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Keywords | 制御性T細胞 / VEGFR2 / FOXP3 / 細胞障害性T細胞 / 抗腫瘍効果 |
|---|
| Research Abstract |
Relation between the number of tumor-infiltrated VEGFR2+ regulatory T (Treg) cells and prognosis in colorectal cancer patients with curative surgical resection was analyzed. The number of tumor-infiltrated VEGFR2+FOXP3+Treg cells was an independent prognostic factor for colorectal cancer. These results indicate the validity that VEGFR2+ Treg could be a therapeutic target. In vitro experiment, protein-bound polysaccharide, basiliximab, Cox-2 inhibitor and bevacizumab significantly reduced Treg number. Activate T lymphocytes induced after the depletion of Treg using basiliximab showed the increase of cytotoxicity against cancer cells.
|
